SCM
ABUS icon

Saba Capital Management’s Arbutus Biopharma ABUS Stock Holding History

Saba Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-347,885
Closed -$1.67M – 393
2025
Q4 		$1.67M Sell
347,885
-330,886
-49% -$1.49M 0.05% 176
2025
Q3 		$3.08M Sell
678,771
-581,358
-46% -$2.14M 0.08% 135
2025
Q2 		$3.89M Buy
1,260,129
+280,613
+29% +$932K 0.09% 118
2025
Q1 		$3.42M Buy
979,516
+91,523
+10% +$305K 0.09% 90
2024
Q4 		$2.9M Buy
887,993
+211,566
+31% +$778K 0.07% 105
2024
Q3 		$2.6M Buy
676,427
+25,000
+4% +$95.9K 0.05% 134
2024
Q2 		$2.01M Buy
651,427
+277,967
+74% +$834K 0.03% 141
2024
Q1 		$964K Buy
+373,460
New +$967K 0.02% 169

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return